MX2024013839A - Composiciones farmaceuticas de glp1 - Google Patents

Composiciones farmaceuticas de glp1

Info

Publication number
MX2024013839A
MX2024013839A MX2024013839A MX2024013839A MX2024013839A MX 2024013839 A MX2024013839 A MX 2024013839A MX 2024013839 A MX2024013839 A MX 2024013839A MX 2024013839 A MX2024013839 A MX 2024013839A MX 2024013839 A MX2024013839 A MX 2024013839A
Authority
MX
Mexico
Prior art keywords
glp1
pharmaceutical compositions
fluoro
oxoimi
dimethyloxan
Prior art date
Application number
MX2024013839A
Other languages
English (en)
Spanish (es)
Inventor
Lee Joseph Burns
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2024013839A publication Critical patent/MX2024013839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2024013839A 2022-05-11 2024-11-08 Composiciones farmaceuticas de glp1 MX2024013839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2024013839A true MX2024013839A (es) 2024-12-06

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013839A MX2024013839A (es) 2022-05-11 2024-11-08 Composiciones farmaceuticas de glp1

Country Status (17)

Country Link
US (1) US20250302809A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522129A1 (cg-RX-API-DMAC7.html)
JP (2) JP7767651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250002778A (cg-RX-API-DMAC7.html)
CN (1) CN119173255A (cg-RX-API-DMAC7.html)
AR (1) AR129296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023269995A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253043A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003392A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015285A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000232A (cg-RX-API-DMAC7.html)
IL (1) IL316629A (cg-RX-API-DMAC7.html)
JO (1) JOP20240245A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013839A (cg-RX-API-DMAC7.html)
PE (2) PE20260136A1 (cg-RX-API-DMAC7.html)
TW (2) TW202508581A (cg-RX-API-DMAC7.html)
WO (1) WO2023220109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
KR20260118441A (ko) * 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
PL3984523T3 (pl) * 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ,インク. ソマトスタチン調節因子の製剤
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1

Also Published As

Publication number Publication date
TWI867526B (zh) 2024-12-21
JOP20240245A1 (ar) 2024-11-05
TW202508581A (zh) 2025-03-01
PE20251285A1 (es) 2025-05-14
IL316629A (en) 2024-12-01
WO2023220109A1 (en) 2023-11-16
CA3253043A1 (en) 2023-11-16
JP2026021422A (ja) 2026-02-10
CL2024003392A1 (es) 2025-03-14
AR129296A1 (es) 2024-08-07
TW202410894A (zh) 2024-03-16
CN119173255A (zh) 2024-12-20
PE20260136A1 (es) 2026-01-21
AU2023269995A1 (en) 2024-11-14
US20250302809A1 (en) 2025-10-02
DOP2024000232A (es) 2024-12-30
JP7767651B2 (ja) 2025-11-11
EP4522129A1 (en) 2025-03-19
KR20250002778A (ko) 2025-01-07
JP2025515706A (ja) 2025-05-20
CO2024015285A2 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
DOP2024000232A (es) Composiciones farmacéuticas de glp1
DOP2024000235A (es) Composiciones de comprimidos de glp1
Ellepola et al. Oral candidal infections and antimycotics
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
PE20081266A1 (es) Anticuerpos e inmunoconjugados
GEP20247638B (en) Pharmaceutical combination of prmt5 inhibitors
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
CO5590918A2 (es) Formulaciones
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
Elguezabal et al. Inhibition of adherence of Candida albicans and Candida dubliniensis to a resin composite restorative dental material by salivary secretory IgA and monoclonal antibodies
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
MA42946B1 (fr) Sels et formes solides d'un antibiotique de type monobactame
NZ776354A (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
AR058085A1 (es) Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
DE69518237D1 (de) Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff
DOP2024000269A (es) Composiciones y uso de la tirzepatida
MA48944B1 (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
MA29567B1 (fr) (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one
CA2393523A1 (fr) Association de cyamemazine et d'un neuroleptique atypique
PE20050629A1 (es) PROFARMACO DE SULFONA DEL ACIDO 6-ß-HIDROXIMETILPENICILANICO COMO INHIBIDOR DE BETA-LACTAMASA
WO2025186786A8 (en) Oral pharmaceutical composition of pitavastatin and ezetimibe, method and uses thereof